Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
Muselaers CH, Stillebroer AB, Desar IM, Boers-Sonderen MJ, van Herpen CM, de Weijert MC, Langenhuijsen JF, Oosterwijk E, Leenders WP, Boerman OC, Mulders PF, Oyen WJ. Muselaers CH, et al. Among authors: mulders pf. J Nucl Med. 2014 Feb;55(2):242-7. doi: 10.2967/jnumed.113.131110. Epub 2014 Jan 6. J Nucl Med. 2014. PMID: 24396030 Free article. Clinical Trial.
Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, Debruyne FM, de Mulder PH, Oosterwijk E, Mulders PF. Oosterwijk-Wakka JC, et al. Among authors: mulders pf. J Immunother. 2002 Nov-Dec;25(6):500-8. doi: 10.1097/00002371-200211000-00006. J Immunother. 2002. PMID: 12439347 Clinical Trial.
Correspondence re: Y. S. Haviv, J. L. Blackwell, A. Kanerva, P. Nagi, V. Krasnykh, I. Dmitriev, M. Wang, S. Naito, X. Lei, A. Hemminki, D. Carey, and D. T. Curiel, Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res., 62: 4273-4281, 2002.
Jongmans W, Tiemessen DM, Oosterwijk E, Mulders PF. Jongmans W, et al. Among authors: mulders pf. Cancer Res. 2003 Apr 15;63(8):1994-5. Cancer Res. 2003. PMID: 12702594 No abstract available.
Immunotherapy for renal cell carcinoma.
Bleumer I, Oosterwijk E, De Mulder P, Mulders PF. Bleumer I, et al. Among authors: mulders pf. Eur Urol. 2003 Jul;44(1):65-75. doi: 10.1016/s0302-2838(03)00191-x. Eur Urol. 2003. PMID: 12814677 Review.
Targeting of adenovirus to human renal cell carcinoma cells.
Jongmans W, van den Oudenalder K, Tiemessen DM, Molkenboer J, Willemsen R, Mulders PF, Oosterwijk E. Jongmans W, et al. Among authors: mulders pf. Urology. 2003 Sep;62(3):559-65. doi: 10.1016/s0090-4295(03)00378-9. Urology. 2003. PMID: 12946777
Tumor antigens and markers in renal cell carcinoma.
Mulders P, Bleumer I, Oosterwijk E. Mulders P, et al. Urol Clin North Am. 2003 Aug;30(3):455-65. doi: 10.1016/s0094-0143(03)00024-7. Urol Clin North Am. 2003. PMID: 12953748 Review.
Monoclonal antibody-based therapy for renal cell carcinoma.
Oosterwijk E, Divgi CR, Brouwers A, Boerman OC, Larson SM, Mulders P, Old LJ. Oosterwijk E, et al. Urol Clin North Am. 2003 Aug;30(3):623-31. doi: 10.1016/s0094-0143(03)00028-4. Urol Clin North Am. 2003. PMID: 12953760 Review.
246 results